DEEPIKA PAKIANATHAN - 08 Jun 2022 Form 4 Insider Report for Karyopharm Therapeutics Inc. (KPTI)

Role
Director
Signature
/s/ Matthew T. Potter, Attorney-in-Fact for Deepika Pakianathan
Issuer symbol
KPTI
Transactions as of
08 Jun 2022
Net transactions value
-$3,434,798
Form type
4
Filing time
10 Jun 2022, 17:20:57 UTC
Previous filing
03 Jun 2022
Next filing
31 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KPTI Common Stock Sale $2,099,428 -322,825 -14% $6.50 1,918,298 08 Jun 2022 See footnote F1, F2
transaction KPTI Common Stock Sale $20,498 -3,152 -14% $6.50 18,731 08 Jun 2022 See footnote F1, F3
transaction KPTI Common Stock Sale $1,294,390 -209,455 -11% $6.18 1,708,843 09 Jun 2022 See footnote F1, F2
transaction KPTI Common Stock Sale $12,638 -2,045 -11% $6.18 16,686 09 Jun 2022 See footnote F1, F3
transaction KPTI Common Stock Sale $7,766 -1,294 -0.08% $6.00 1,707,549 10 Jun 2022 See footnote F1, F2
transaction KPTI Common Stock Sale $78.02 -13 -0.08% $6.00 16,673 10 Jun 2022 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $6.00 to $6.64, inclusive. The Reporting Person has provided to the issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
F2 The shares are held directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII"), is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.
F3 The shares are held directly by Delphi BioInvestments VIII, L.P. ("DB VIII"). DMP VIII is the general partner of each of DB VIII and DV VIII. The Reporting Person is a managing member of DMP VIII. As a managing member of DMP VIII, the Reporting Person shares voting and investment power over the securities held by DB VIII and DV VIII, and may be deemed to have indirect beneficial ownership of such shares. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his proportionate pecuniary interest therein.